X4 Pharmaceuticals Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is X4 Pharmaceuticals Inc's ROA in the second quarter of 2026?
X4 Pharmaceuticals Inc recorded a cumulative net loss of $-90 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -36.41%.

However, within the Healthcare sector 468 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3905, from total ROA ranking in the first quarter of 2026 at 4546.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	152.9 %	107.89 %	98.34 %	-8.2 %	-50.07 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-90	-100	-79	-95	-102
Return On Assets (TTM)	-36.41 %	-48.09 %	-45.97 %	-69.77 %	-72.87 %
XFOR's Total Ranking	# 3905	# 4546	# 4204	# 4285	# 711
Total Assets (TTM) in million	266	270	290	164	105
Seq. Total Assets Change	-1.6 %	-6.95 %	77.59 %	55.52 %	-19.11 %
Seq. Net Income Change	-	-	-	-	-

XFOR's 5 Years Annual ROA >> Back to XFOR Management Effectiveness >> Compare XFOR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 55
Sector	# 469
Overall	# 3719

Return On Assets Statistics
High	Average	Low
10.96 %	-56.11 %	-100.4 %
		(Sep 30 2022)

Financial Statements
X4 Pharmaceuticals Inc's Assets	$ 266 million	XFOR's Balance sheet
X4 Pharmaceuticals Inc's Income	$ -16 million	Quarterly XFOR's Income Statement
XFOR's Income by Division		See XFOR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	98.34 %	-52.02 %	96.18 %	32.78 %	-4.47 %
Total Assets in million	290	146	305	156	117
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-79	-37	-101	-96	-103
Annual Return On Assets	-27.27 %	-25.57 %	-33.15 %	-61.97 %	-87.59 %

XFOR's 5 Years Annual ROA >> Back to XFOR Management Effectiveness >> Compare XFOR ROA to its Competitors

More Return On Assets Ratios
XFOR's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
XFOR's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for XFOR's Competitors
Subscribers only: Roa for X4 Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for XFOR's Customers

You may also want to know
XFOR's Roi	XFOR's Inventory Turnover Ratio	XFOR's Growth Rates	XFOR's Dividend Comparisons
	XFOR's Profitability Ratios	XFOR's Asset Turnover Ratio	XFOR's Dividend Growth
XFOR's Roe	XFOR's Valuation Ratios	XFOR's Financial Strength Ratios	XFOR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T22:56:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.